The continuation of Cancer Improved Improved Cancer Cancer Institute Service Networks National Cancer Cancer $932,091.60 16/03/2009 56 Alexandria, NSW 1435 Australia NSW Demonstration Program Control Control (CanNET) in New South Wales Priority Driven Collaborative Priority Driven Cancer Research Scheme Collaborative (PDCCRS) 2008: Development Cancer Cancer University of NSW of an optimised $474,650 15/06/2009 61 Sydney 2052 Australia Research multidisciplinary intervention Scheme for post-cancer fatigue. App568828. CA-A0809/64 Priority Driven Collaborative Cancer Research Scheme Priority Driven (PDCCRS) 2009: A Collaborative Cancer University of combinatorial approach Cancer $321,028.95 01/01/2010 36 Adelaide 5005 Australia Adelaide targeting androgen signalling Research for treatment of prostate Scheme cancer. App627229. Priority Driven Collaborative Cancer Research Scheme Priority Driven (PDCCRS) 2009: Development Collaborative Cancer University of South of microfluidic chips to isolate Cancer $24,750 06/01/2010 12 Adelaide 5001 Australia Australia and analyse peripheral blood Research cell populations in pancreatic Scheme cancer patients. App631921. CA-A0910/56 Priority Driven Collaborative Priority Driven Cancer Research Scheme Collaborative Cancer Ludwig Institute of (PDCCRS) 2009: Mechanisms Cancer $216,150 18/01/2010 36 Heidelberg 3084 Australia Cancer Research of abiraterone resistance in Research prostate cancer. App603107. Scheme CA-A0910/57 Priority Driven Collaborative Priority Driven Cancer Research Scheme Collaborative (PDCCRS) 2009: Identifying Cancer Garvan Institute of Cancer and targeting Docetaxel $213,950 20/01/2010 36 Darlinghurst 2010 Australia Medical Research Research resistance in hormone Scheme refractory prostate cancer. App596858. CA-A0910/54 Priority Driven Collaborative Priority Driven Cancer Research Scheme Collaborative (PDCCRS) 2009: The role of Cancer Cancer Monash University the EphA3 receptor in the $24,750 20/01/2010 12 Clayton 3168 Australia Research stromal microenvironment of Scheme tumours. App606719.
Cancer Australia Improved Cancer Control Improved Cancer Control Cancer Institute NSW The continuation of Cancer Service Networks National Demonstration Program (CanNET) in New South Wales $932,091.60 16/03/2009 56 Alexandria, NSW 1435 Cancer Australia Priority Driven Collaborative Cancer Research Scheme University of NSW Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Development of an optimised multidisciplinary intervention for post-cancer fatigue. App568828. CA-A0809/64 $474,650 15/06/2009 61 Sydney 2052 Cancer Australia Priority Driven Collaborative Cancer Research Scheme University of Adelaide Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: A combinatorial approach targeting androgen signalling for treatment of prostate cancer. App627229. $321,028.95 01/01/2010 36 Adelaide 5005 Cancer Australia Priority Driven Collaborative Cancer Research Scheme University of South Australia Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Development of microfluidic chips to isolate and analyse peripheral blood cell populations in pancreatic cancer patients. App631921. CA-A0910/56 $24,750 06/01/2010 12 Adelaide 5001 Cancer Australia Priority Driven Collaborative Cancer Research Scheme Ludwig Institute of Cancer Research Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Mechanisms of abiraterone resistance in prostate cancer. App603107. CA-A0910/57 $216,150 18/01/2010 36 Heidelberg 3084 Cancer Australia Priority Driven Collaborative Cancer Research Scheme Garvan Institute of Medical Research Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Identifying and targeting Docetaxel resistance in hormone refractory prostate cancer. App596858. CA-A0910/54 $213,950 20/01/2010 36 Darlinghurst 2010 Cancer Australia Priority Driven Collaborative Cancer Research Scheme Monash University Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: The role of the EphA3 receptor in the stromal microenvironment of tumours. App606719. $24,750 20/01/2010 12 Clayton 3168
grants_reporting_20170703.docx